Submission of Matters to a Vote of Security Holders

Business Context and Reporting Period

This Form 8-K filing by Ekso Bionics Holdings, Inc. (trading symbol: EKSO) covers events occurring on March 12, 2020, and March 17, 2020. The report details the results of a special meeting of stockholders and updates regarding the company's compliance status with Nasdaq listing requirements. The filing does not contain financial performance data for a specific reporting period.

Key Financial Metrics

The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only quantitative data presented relates to stockholder voting results and share counts.

Material Changes and Corporate Actions

Stockholder Vote Results (March 12, 2020)

Out of 86,919,512 shares outstanding, 61,361,730 shares were present, constituting a quorum. Stockholders approved three proposals:

  • Proposal One (Reverse Stock Split): Approved amendments to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-15.
    • Votes For: 46,972,236
    • Votes Against: 14,099,914
    • Votes Abstained: 289,580
  • Proposal Two (Equity Plan Amendment): Approved increasing the number of shares authorized for grant under the 2014 Equity Incentive Plan from 12,614,290 to 17,614,290 shares.
    • Votes For: 27,493,430
    • Votes Against: 6,259,768
    • Votes Abstained: 397,581
    • Broker Non-Votes: 27,210,951
  • Proposal Three (Adjournment): Approved the ability to adjourn the meeting to solicit additional proxies if necessary.
    • Votes For: 46,923,131
    • Votes Against: 13,430,874
    • Votes Abstained: 1,007,725

Nasdaq Compliance Status

The company received a deficiency notice from Nasdaq in September 2019 due to its stock price trading below $1.00 per share for 30 consecutive business days. The initial compliance deadline of March 16, 2020, was missed. On March 17, 2020, Nasdaq granted a second compliance period of 180 days, extending the deadline to September 14, 2020.

Guidance, Outlook, and Risks

Outlook: Management intends to implement the approved reverse stock split promptly following necessary filings to regain compliance with the Nasdaq minimum bid price requirement.

Risks and Contingencies:

  • Delisting Risk: If the company fails to maintain a closing bid price of at least $1.00 per share for 10 consecutive business days before September 14, 2020, the stock will be subject to delisting.
  • Appeal Uncertainty: While the company may appeal a delisting determination to a Nasdaq Hearing Panel, there is no assurance that continued listing will be granted during the appeal process.
  • Execution Risk: There is no assurance that the reverse stock split will successfully satisfy the bid price requirement or other Nasdaq rules.

Investor Verification Checklist

  • Verify the exact reverse stock split ratio selected by the Board of Directors within the approved 1-for-5 to 1-for-15 range.
  • Monitor the daily closing bid price of EKSO stock to ensure it meets the $1.00 threshold for 10 consecutive business days before the September 14, 2020 deadline.
  • Confirm the filing of the amendment to the Articles of Incorporation with the state of Nevada and Nasdaq.
  • Review the impact of the increased equity plan authorization on potential future dilution.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.